Clinical construct design consultation
VVMF to unlock the future of medicine
VVMF has a vision to be a leading commercial viral vector contract development and manufacturing organisation (CDMO), partnering to deliver advanced therapeutic solutions to patients globally and services regionally.
We are pioneering the research, development and manufacturing of high-quality, clinical and commercial grade viral vectors, a critical component of innovative lifesaving advanced therapeutic treatments.
Partnering for Success
VVMF is the first commercial manufacturing facility of its kind in Australia, being uniquely integrated in the largest health, education, research and innovation precinct in the country.
Supported by a world-class clinical trial ecosystem, VVMF will design, develop and manufacture viral vector solutions for companies, customers and patients in partnership.
Global and Regional Value Creation
VVMF is perfectly placed to become a regional catalyst for viral vector research and innovation together with commercial-scale delivery of viral vectors to Asia Pacific and the world.
This will be achieved by world leading viral vector experts, globally approved regulatory standards, optimised processes and consistency of quality at its core.
VVMF provides solutions for unmet medical needs requiring the benefit of viral vector derived advanced therapeutics.
This is supported by an economically stable political environment with attractive financial incentives found in Australia.
Delivers Technical Excellence in LV and AAV Manufacturing
News
Diversity Disclosure 2023-2024
Viral Vector Manufacturing Facility Pty. Ltd. (“VVMF”, “the Company”) has adopted a Diversity Policy. This Policy requires disclosure regarding: The VVMF Board of Directors (“Board”)…
VVMF announces appointment of the Board
The Viral Vector Manufacturing Facility Pty Ltd (VVMF) is delighted to announce the following appointments to the Board. Sue MacLeman: VVMF Board Chair and Non-Executive…
Expert Leadership
VVMF BOARD
- Sue MacLeman
Board Chair and Non-Executive Director
View Bio
Sue MacLeman is a highly respected industry executive with more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive, having held senior roles as CEO and Board member of several ASX, AIM and NASDAQ listed companies in the healthtech sector.
Additional to her role with VVMF, she is currently Non-Executive Director at Planet Innovation Holdings, Smartways Logistics, Rhythm Biosciences Ltd, Australian Academy of Technology and Engineering (ATSE) and Omico.
Sue is also appointed to several industry, academic and government advisory boards including CSIRO, Health Systems Security Australia, Asialink Business and the NSW Innovation and Productivity Council. She is also an industry mentor across a number of programs. Her broad commercial and technical experience is underpinned by a Bachelor of Pharmacy from the University of Queensland, a Master of Laws from Deakin University and a Master of Marketing from Melbourne Business School. She is also a Fellow of ATSE and Fellow/Graduate of Australian Institute of Company Directors (AICD).
- Dr. Jane Ryan
Non-Executive Director, Chair of Remuneration & Nomination Committee
View Bio
Jane Ryan is a technically qualified Non-Executive Director with a strong international career and experience at Board and Executive level in business development, capital raising, M&A, partnering, ASX and NASDAQ reporting. Additionally, Jane has strong governance experience in listed, not-for-profit, government statuary bodies and unlisted companies. Jane has held executive roles at Sementis, Biota (now Vaxart), and Peptech.
In addition to her role with VVMF, Jane is also currently:
- Non-Executive Director – IDT Australia (ASX: IDT)
- Non-Executive Director – Bionomics Ltd (NASDAQ: BNOX)
Jane has previously held roles as a Board Member of Diabetes Australia, Victoria; TechInSA, Victorian Endowment for Science, Knowledge and Innovation (VESKI) and Anatara Lifesciences. Jane has a PhD in Immunology / Biochemistry and was a Postdoctoral Research Fellow, Pharmaceuticals at Columbia University.
- Trevor Danos AM
Non-Executive Director, Chair of Risk and Audit Committee
View Bio
Trevor Danos is a highly respected company director and adviser for a range of government and private organisations, with a focus on areas of finance, infrastructure, regulated businesses, health, procurement reform and science / innovation.
Trevor was a senior lawyer with tertiary qualifications in Law, Economics and Science. He is chair of Northern Sydney Local Health District and sits on the boards of Endeavour Energy and the privatised NSW Land Registry Office. He is an Adjunct Professor at UNSW and previous Chair of the Dean of Science Advisory Council. Previously Trevor was a senior member of the Commonwealth Treasury Reference Group for the establishment of the National Housing Finance and Investment Corporation.
Trevor is a published author: “Pursuit of Excellence: A History of the Professor Harry Messel International Science School”, and is a “Male Champion of Change” (“Champions of Change Coalition”).
- Robyn Kruk AO
Non-Executive Director
View Bio
Robyn Kruk brings a wealth of relevant senior executive experience at a state and national level, that includes health care policy and broader regulatory settings. Robyn has led state and Australian Government agencies, including as Secretary of NSW Health and NSW Department of Premier and Cabinet, Secretary of the Commonwealth Department of the Environment, Water, Heritage and the Arts, and the inaugural CEO of the National Mental Health Commission.
She has chaired and served on statutory boards and advisory entities relating to health care quality and safety, food standards, eating disorders, disability, emergency management and environmental protection and resource management.
Robyn has led a range of independent reviews such as the 2023 Independent Review of Overseas Health Practitioner Regulatory Settings and in 2022 the New South Wales Health COVID-19 System Response Debrief. In 2021, Robyn led the Second Year Review of the National Redress Scheme and the Ministerial Taskforce into Public Mental Health Services for Children and Adolescents in Western Australia, and in 2019, the Western Australian Government’s Sustainable Health Review.
VVMF Executives
- Stephen Thompson
Chief Executive Officer
View Bio
Stephen Thompson brings extensive leadership and management experience to VVMF with a strong global track record in Enterprise Leadership, Manufacturing and Operations, Commercial, Business development and alliance partnerships, in market leading multinational companies including Baxter International Inc, Icon Group, Nestlé, Pacific Dunlop, and Proctor & Gamble.
Having obtained a 1st class Bachelor of Engineering (Chemical) (Hons) degree from UNSW, Sydney, Australia and working across both multinationals and the Ingham Institute for Applied Medical Research, Stephen is very well equipped to lead the VVMF as the first CEO.
Stephen is a trusted and authentic leader, with recognised skills in mentoring and developing people and enhancing employee engagement. He has a passion for developing high performing teams to ensure organisations deliver successfully through empowering people to challenge the status quo, embrace change with positive resilience, and have a thirst for innovation and continuous improvement. Achieving sustained business success by leveraging agile strategic thinking, superior organisational and communication skills and strong interpersonal connections both internally and externally at all levels.
VVMF ADVISORS
- Prof. Ian Alexander
PhD / BMedSci / MBSS / FRACP / HGSACG / FAHMS
View Bio
Ian Alexander is a Professor in Paediatrics and Molecular Medicine at the University of Sydney, Senior Staff Specialist in Genetic Medicine at The Children’s Hospital at Westmead, and Head of the Sydney Children’s Hospitals Network and Children’s Medical Research Institute Gene Therapy Research Unit.
As a clinician-scientist he has dedicated his career to the development of novel therapies for infants and children with devastating genetic disease and is internationally renowned for his leadership in pioneering the gene therapy field in Australia. He has made ground-breaking contributions along the entire translational pathway, from the basic science of viral vector-mediated gene transfer to the implementation of globally significant paediatric gene therapy clinical trials.
Peer recognition includes election as a fellow of the Australian Academy of Health and Medical Science in 2015, the National Health and Medical Research Council Marshall and Warren Award in 2020 and the Research Australia Peter Wills Medal in 2022.
- A. Prof. Leszek Lisowski
PhD / MBA
View Bio
Leszek [pronounced: Leshek] Lisowski, is a world vectorology expert with over 20 years of experience in developing, manufacturing, functional validation and translation of viral vectors for human gene therapies.
In 2015, Leszek was recruited by Children’s Medical Research Institute (CMRI) / The University of Sydney to establish and run the Vector and Genome Engineering Facility (VGEF) and to establish his independent research program, the Translational Vectorology Research Unit (TVRU).
In addition to being Unit Head at CMRI, Leszek is a conjoint Associate Professor at the University of Sydney, holds the title of Honorary Faculty at University College London (UCL), London, UK and the title of Visiting Associate Professor at the Military Institute of Medicine-National Research Institute in Warsaw, Poland.
He serves as a reviewer for a number of leading journals in the field of gene therapy, a reviewer for national and international funding agencies and serves on a number of academic, government and commercial advisory and scientific review boards.
